Abstract: The present disclosure relates to salts of heterocyclic compounds and methods that inhibit HIF pathway activity. The compounds are designed to treat or prevent cancer and other hypoxia-mediated diseases.

Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.

Abstract: A disconnect assembly configured to disconnect a parachute of an aerial delivery apparatus from a payload includes a detector device, a disconnect device, and a transmit cable. The detector device is configured to detect that the aerial delivery apparatus has landed, the disconnect device is configured to provide a releasable connection between the parachute and the payload, and the transmit cable is configured to transmit a mechanical trigger force from the detector device to the disconnect device. When the detector device detects that the aerial delivery apparatus has landed, the transmit cable transmits a mechanical trigger force from the detector device to the disconnect device and the disconnect device releases the connection between the parachute and the payload.

Abstract: An acoustic field may be produced from a transducer array having known relative positions and orientations in this acoustic field, one or more control points may be defined. An amplitude may be assigned to the control point. Mid-air haptic effect for a virtual object on a human body part may be generated by moving the control point in a single closed curve comprising a plurality of curve segments. The single closed curve traverses at least one location where the human body part intersects with the virtual object. Additionally, a user may interact with virtual three-dimensional content using the user's hands while a tracking system monitoring the user's hands, a physics engine updates the properties of the virtual three-dimensional content and a haptic feedback system provides haptic information to the user.

Abstract: Storage-stable compositions comprising soil release polymers. Compositions are described comprising A) of from 45 to 55% by weight of one or more polyesters according to the following formula (I) wherein R and R2 independently of one another are X—(OC2H4) n—(OC3H6)m wherein X is C1-4alkyl, the —(OC2H4) groups and the —(OC3H6) groups are arranged block-wise and the block consisting of the —(OC3H6) groups is bound to a COO group or are HO—(C3H6) n is based on a molar average a number of from 12 to 120, m is based on a molar average a number of from 1 to 10, and a is based on a molar average a number of from 4 to 9, and B) of from 10 to 30% by weight of one or more alcohols selected from the group consisting of ethylene glycol, 1,2-propylene glycol, 1,3 -propylene glycol, 1,2 -butylene glycol, 1,3 -butylene glycol, 1,4 -butylene glycol and butyl glycol and C) of from 24 to 42% by weight of water, the amounts in each case being based on the total weight of the composition.

Abstract: A facility for event failure management is provided, which includes providing a failed event database containing failed event information relating to failed events and one or more components associated with each of the failed events. Upon modification to a component associated with a failed event, the failed event is retried. Based on a result of retrying the failed event, failed event information of the failed event database is updated. The failed event database may therefore be dynamically and/or automatically updated so that it contains up-to-date and appropriate information for predicting and/or managing event failures.

Abstract: A method and system for modifying virtual reality (VR) boundaries based on usage includes defining, using a virtual reality system including a computer communicating with head set, a safe area defining a geographic location for a user. The safe area is monitored for when the user strays into a second area beyond the safe area. The second area is defined in relation to the safe area that the user strayed into beyond the safe area. The user interaction in the second area beyond the safe area for safety is assessed, and a determination is made when the second area is safe based on a criteria. In response to the determining that the second area is safe, not initiating an alert to the user of being outside the safe area.

Abstract: Augmenting a video stream of an environment is provided, the environment containing a private entity to be augmented. Video of the environment is processed in accordance with an entity recognition process to identify the presence of at least part of an entity in the environment. It is determined whether the identified entity is to be augmented based on information relating to the identified entity and the private entity. Based on determining that the identified entity is to be augmented, the video stream is modified to replace at least a portion of the identified entity with a graphical element adapted to obscure the portion of the identified entity in the video stream. By modifying the video stream to obscure an entity, private or personal information in the environment may be prevented from being displayed to a viewer of the video stream.

Abstract: Disclosed herein is the compound (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido)pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide, and salt forms and polymorphs thereof demonstrating improved exposure after oral dosing. Methods of inhibition GLS1 activity in a human or animal subject are also provided.

Abstract: The present invention relates to compounds and methods useful as inhibitors of KDM5 for the treatment or prevention of cancer.

Abstract: The present invention relates to compounds which may be useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.

Abstract: An acoustic field may be produced from a transducer array having known relative positions and orientations In this acoustic field, one or more control points may be defined. An amplitude may be assigned to the control point. Mid-air haptic effect for a virtual object on a human body part may be generated by moving the control point in a single closed curve comprising a plurality of curve segments. The single closed curve traverses at least one location where the human body part intersects with the virtual object. Additionally, a user may interact with virtual three-dimensional content using the user's hands while a tracking system monitoring the user's hands, a physics engine updates the properties of the virtual three-dimensional content and a haptic feedback system provides haptic information to the user.

Abstract: Disclosed herein are compounds which inhibit the kinase activity of dual leucine zipper (DLK) kinase (MAP3K12), pharmaceutical compositions, and methods of treatment of DLK-mediated diseases, such as neurological diseases that result from traumatic injury to central nervous system and peripheral nervous system neurons (e.g. stroke, traumatic brain injury, spinal cord injury), or that result from a chronic neurodegenerative condition (e.g. Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, progressive supranuclear palsy, Lewy body disease, Kennedy's disease, and other related conditions), from neuropathies resulting from neurological damage (chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and related conditions) and from cognitive disorders caused by pharmacological intervention (e.g. chemotherapy induced cognitive disorder, also known as chemobrain).

Abstract: The present invention relates to heterocyclic compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.

Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.

Abstract: The invention relates to an antigen binding site for binding to a P2X7 receptor, the antigen binding site being defined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

Abstract: The present invention provides an aqueous polyurethane dispersion (PUD) comprising an amorphous polyester having a glass transition temperature (Tg) as determined by differential scanning calorimetry of less than ?30° C.; wherein the aqueous polyurethane dispersion (PUD) has a glass transition temperature (Tg) as determined by differential scanning calorimetry (DSC) of 0° C. to 20° C. and a hard block content of greater than 50%.

Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.

Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.

Abstract: The present invention relates to tetrahydropyrido[4,3-d]pyrimidine based compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.